drugset / Trial / NCT06562946
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function
Non-randomizedSingle-groupOpen-labelOther
Summary
This is a phase 1, open-label, parallel-group, single-center study to evaluate the pharmacokinetics and safety of a single 25 mg oral dose of pimicotinib in subjects with mild and moderate hepatic impairment and in control subjects with normal hepatic function.
Timeline
- Start
- 2024-09-20
- Primary completion
- 2024-12-30
- Completion
- 2025-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimicotinib | Small molecule | 25 mg | Oral |
Indications
No indication recorded.